Literature DB >> 25132069

Decreased lipases and fatty acid and glycerol transporter could explain reduced fat in diabetic morbidly obese.

Roser Ferrer1, Eva Pardina, Joana Rossell, Juan Antonio Baena-Fustegueras, Albert Lecube, José María Balibrea, Enric Caubet, Oscar González, Ramón Vilallonga, Jose Manuel Fort, Julia Peinado-Onsurbe.   

Abstract

OBJECTIVE: The possible differences were investigated in 32 morbidly obese patients depending on whether they were "healthy" or had dyslipidemia and/or type 2 diabetes.
METHODS: Lipid metabolism and insulin resistance were analyzed in subcutaneous (SAT) and visceral adipose tissue (VAT) before and during 6 and 12 months after Roux-en-Y gastric bypass.
RESULTS: Significant differences have been found in lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL) activities in SAT from the different obese group versus normal weight (control) but not between them. The reduced lipase activities in VAT were 43 and 19% smaller (22 and 4% smaller, respectively, vs. control) than the "healthy" obese group for LPL and HSL, respectively, and were accompanied with a reduced expression of these lipases, as well as decreased expression of FAT/CD36, FABP4, and AQ7 in that tissue. In addition, the expression of the other genes measured showed a downregulation not only versus the "healthy" obese but also versus the normal weight group.
CONCLUSIONS: Being obese is not "healthy," but it is even less so if morbidly obese patients with diabetes and dyslipidemia were considered. The reduced fat accumulation in these patients may be attributed to the decrease of the expression and activity of the lipases of their adipose tissue.
© 2014 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25132069     DOI: 10.1002/oby.20861

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  7 in total

Review 1.  Does bariatric surgery improve adipose tissue function?

Authors:  H Frikke-Schmidt; R W O'Rourke; C N Lumeng; D A Sandoval; R J Seeley
Journal:  Obes Rev       Date:  2016-06-08       Impact factor: 9.213

2.  Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery.

Authors:  E Pardina; R Ferrer; J Rossell; D Ricart-Jané; K A Méndez-Lara; J A Baena-Fustegueras; A Lecube; J Julve; J Peinado-Onsurbe
Journal:  Int J Obes (Lond)       Date:  2017-05-10       Impact factor: 5.095

3.  Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese.

Authors:  Eva Pardina; Roser Ferrer; Joana Rossell; Juan Antonio Baena-Fustegueras; Albert Lecube; Jose Manuel Fort; Enric Caubet; Óscar González; Ramón Vilallonga; Víctor Vargas; José María Balibrea; Julia Peinado-Onsurbe
Journal:  BBA Clin       Date:  2016-01-08

Review 4.  Implications of Aquaglyceroporin 7 in Energy Metabolism.

Authors:  Francesco Maria Iena; Janne Lebeck
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

5.  Changes of Plasma FABP4, CRP, Leptin, and Chemerin Levels in relation to Different Dietary Patterns and Duodenal-Jejunal Omega Switch Surgery in Sprague-Dawley Rats.

Authors:  Dominika Stygar; Elżbieta Chełmecka; Tomasz Sawczyn; Bronisława Skrzep-Poloczek; Jakub Poloczek; Konrad Wojciech Karcz
Journal:  Oxid Med Cell Longev       Date:  2018-04-22       Impact factor: 6.543

6.  Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet.

Authors:  Caroline Blomquist; Elin Chorell; Mats Ryberg; Caroline Mellberg; Evelina Worrsjö; Elena Makoveichuk; Christel Larsson; Bernt Lindahl; Gunilla Olivecrona; Tommy Olsson
Journal:  Eur J Nutr       Date:  2017-10-26       Impact factor: 5.614

7.  Changes in adipose tissue lipolysis gene expression and insulin sensitivity after weight loss.

Authors:  Monika Karczewska-Kupczewska; Agnieszka Nikołajuk; Radosław Majewski; Remigiusz Filarski; Magdalena Stefanowicz; Natalia Matulewicz; Marek Strączkowski
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.